| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.602 | 0.005 | 0.602 | MAP kinase kinase 6 inhibitor | 0.369 0.079 DBMET00830 | ||
| 0.555 | 0.015 | 0.555 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.337 0.165 DBMET00830 0.291 0.225 DBMET00921 | ||
| 0.491 | 0.012 | 0.491 | Psychostimulant | 0.321 0.038 DBMET00830 0.139 0.127 DBMET00886 0.164 0.104 DBMET00921 | ||
| 0.492 | 0.031 | 0.492 | Calcium channel L-type activator | 0.463 0.044 DBMET00830 0.262 0.193 DBMET00886 0.324 0.137 DBMET00921 | ||
| 0.42 | 0.014 | 0.42 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.14 0.096 DBMET00830 | ||
| 0.423 | 0.017 | 0.423 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.309 0.058 DBMET00830 0.223 0.132 DBMET00886 0.264 0.093 DBMET00921 | ||
| 0.412 | 0.016 | 0.412 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.156 0.106 DBMET00830 0.162 0.102 DBMET00921 | ||
| 0.393 | 0.004 | 0.393 | 5 Hydroxytryptamine 1D antagonist | 0.123 0.016 DBMET00921 | ||
| 0.377 | 0.008 | 0.377 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.248 0.068 DBMET00830 | ||
| 0.37 | 0.005 | 0.37 | 5 Hydroxytryptamine 1 agonist | 0.127 0.016 DBMET00830 | ||
| 0.351 | 0.01 | 0.351 | MAP-kinase-activated kinase 5 inhibitor | 0.22 0.082 DBMET00830 | ||
| 0.348 | 0.01 | 0.377 | 5 Hydroxytryptamine 1E antagonist | 0.298 0.031 DBMET00886 0.377 0.006 DBMET00921 | DBMET00921 | |
| 0.339 | 0.004 | 0.339 | MAP kinase kinase 3 inhibitor | 0.184 0.176 DBMET00886 0.216 0.083 DBMET00921 | ||
| 0.339 | 0.005 | 0.339 | Check point kinase 2 inhibitor | 0.141 0.035 DBMET00830 0.13 0.042 DBMET00921 | ||
| 0.358 | 0.024 | 0.358 | Death-associated protein kinase 3 inhibitor | 0.242 0.055 DBMET00830 0.164 0.103 DBMET00921 | ||
| 0.351 | 0.023 | 0.351 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.18 0.094 DBMET00830 | ||
| 0.344 | 0.017 | 0.344 | Protein kinase C nu inhibitor | 0.149 0.07 DBMET00830 | ||
| 0.32 | 0.004 | 0.32 | GABA C receptor antagonist | 0.271 0.005 DBMET00830 0.099 0.079 DBMET00886 0.128 0.045 DBMET00921 | ||
| 0.321 | 0.007 | 0.321 | 5 Hydroxytryptamine agonist | 0.075 0.044 DBMET00830 0.059 0.056 DBMET00886 0.166 0.019 DBMET00921 | ||
| 0.316 | 0.003 | 0.316 | GABA C receptor rho-1 antagonist | 0.246 0.004 DBMET00830 0.11 0.05 DBMET00921 | ||
| 0.311 | 0.005 | 0.311 | Protein kinase C mu inhibitor | 0.137 0.032 DBMET00830 | ||
| 0.309 | 0.004 | 0.309 | MAP-kinase-activated kinase inhibitor | 0.295 0.004 DBMET00830 | ||
| 0.299 | 0.007 | 0.299 | Death-associated protein kinase 2 inhibitor | 0.181 0.052 DBMET00830 0.148 0.112 DBMET00921 | ||
| 0.294 | 0.004 | 0.294 | Protein kinase C gamma inhibitor | 0.208 0.012 DBMET00830 | ||
| 0.295 | 0.009 | 0.295 | Cyclin-dependent kinase 8 inhibitor | 0.139 0.091 DBMET00830 0.173 0.058 DBMET00886 0.22 0.025 DBMET00921 | ||
| 0.303 | 0.018 | 0.303 | 5 Hydroxytryptamine antagonist | 0.094 0.084 DBMET00886 0.199 0.034 DBMET00921 | ||
| 0.378 | 0.093 | 0.378 | 5 Hydroxytryptamine release inhibitor | 0.271 0.2 DBMET00830 0.297 0.168 DBMET00886 0.351 0.114 DBMET00921 | ||
| 0.277 | 0.004 | 0.277 | MAP-kinase-activated kinase 2 inhibitor | 0.268 0.004 DBMET00830 | ||
| 0.303 | 0.038 | 0.303 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | |||
| 0.265 | 0.002 | 0.265 | 5 Hydroxytryptamine 1D agonist | 0.091 0.004 DBMET00830 0.038 0.015 DBMET00921 | ||
| 0.267 | 0.005 | 0.267 | MAP kinase kinase 5 inhibitor | 0.165 0.1 DBMET00830 0.178 0.066 DBMET00886 0.201 0.032 DBMET00921 | ||
| 0.288 | 0.039 | 0.288 | MAP kinase kinase 2 inhibitor | 0.184 0.092 DBMET00921 | ||
| 0.292 | 0.043 | 0.292 | Anticonvulsant | |||
| 0.278 | 0.034 | 0.278 | Peptidyltransferase inhibitor | 0.261 0.043 DBMET00886 0.246 0.053 DBMET00921 | ||
| 0.27 | 0.026 | 0.27 | Ca2+/calmodulin-dependent kinase II delta inhibitor | |||
| 0.331 | 0.093 | 0.603 | Toll-Like receptor agonist | 0.603 0.017 DBMET00886 0.366 0.074 DBMET00921 | DBMET00886 | |
| 0.244 | 0.006 | 0.244 | 5 Hydroxytryptamine 1B antagonist | 0.067 0.043 DBMET00921 | ||
| 0.311 | 0.076 | 0.311 | Immunomodulator | |||
| 0.239 | 0.006 | 0.239 | MAP kinase kinase 4 inhibitor | 0.157 0.049 DBMET00830 0.129 0.118 DBMET00921 | ||
| 0.325 | 0.095 | 0.6 | Toll-Like receptor 7 agonist | 0.6 0.017 DBMET00886 0.357 0.078 DBMET00921 | DBMET00886 | |
| 0.238 | 0.008 | 0.238 | Protein kinase C zeta inhibitor | 0.163 0.017 DBMET00830 | ||
| 0.234 | 0.004 | 0.234 | 5 Hydroxytryptamine 5A antagonist | 0.061 0.043 DBMET00830 0.064 0.039 DBMET00921 | ||
| 0.235 | 0.008 | 0.235 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.139 0.095 DBMET00886 0.163 0.051 DBMET00921 | ||
| 0.233 | 0.01 | 0.233 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.081 0.05 DBMET00830 | ||
| 0.271 | 0.05 | 0.271 | Tyrosine 3 hydroxylase inhibitor | 0.268 0.053 DBMET00830 | ||
| 0.228 | 0.008 | 0.228 | MAP3K9 inhibitor | 0.2 0.015 DBMET00830 | ||
| 0.234 | 0.021 | 0.273 | Histone deacetylase SIRT1 inhibitor | 0.261 0.015 DBMET00886 0.273 0.012 DBMET00921 | DBMET00921 | |
| 0.253 | 0.044 | 0.253 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.138 0.131 DBMET00830 | ||
| 0.239 | 0.031 | 0.239 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | |||
| 0.213 | 0.006 | 0.213 | I kappa B kinase inhibitor | |||
| 0.208 | 0.005 | 0.208 | 5 Hydroxytryptamine 5 antagonist | 0.07 0.026 DBMET00830 0.054 0.048 DBMET00921 | ||
| 0.234 | 0.03 | 0.234 | Polo-like kinase-3 inhibitor | |||
| 0.26 | 0.063 | 0.26 | Potassium channel (Voltage-sensitive) blocker | 0.151 0.136 DBMET00921 | ||
| 0.22 | 0.024 | 0.22 | Cyclin-dependent kinase 3 inhibitor | 0.147 0.103 DBMET00921 | ||
| 0.212 | 0.016 | 0.239 | Histone deacetylase class III inhibitor | 0.215 0.015 DBMET00886 0.239 0.011 DBMET00921 | DBMET00921 | |
| 0.252 | 0.056 | 0.252 | EphB2 antagonist | |||
| 0.224 | 0.035 | 0.224 | Protein kinase (CK1) gamma 1 inhibitor | |||
| 0.225 | 0.036 | 0.225 | Protein kinase (CK1) gamma inhibitor | |||
| 0.198 | 0.01 | 0.198 | Opioid kappa receptor antagonist | 0.161 0.015 DBMET00886 0.158 0.015 DBMET00921 | ||
| 0.202 | 0.02 | 0.202 | CF transmembrane conductance regulator agonist | 0.129 0.12 DBMET00886 0.147 0.082 DBMET00921 | ||
| 0.209 | 0.028 | 0.209 | 5 Hydroxytryptamine 2 antagonist | 0.113 0.063 DBMET00886 0.196 0.031 DBMET00921 | ||
| 0.219 | 0.044 | 0.219 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.159 0.071 DBMET00830 | ||
| 0.18 | 0.006 | 0.18 | I kappa B kinase 1 inhibitor | |||
| 0.224 | 0.053 | 0.224 | I kappa B kinase epsilon inhibitor | |||
| 0.212 | 0.041 | 0.212 | Protein kinase (CK1) gamma 3 inhibitor | |||
| 0.196 | 0.025 | 0.196 | Protein kinase (CK2) alpha inhibitor | 0.09 0.086 DBMET00830 | ||
| 0.223 | 0.053 | 0.223 | Focal adhesion kinase 2 inhibitor | |||
| 0.164 | 0.005 | 0.164 | I kappa B kinase 2 inhibitor | |||
| 0.186 | 0.027 | 0.218 | Alpha 2b adrenoreceptor antagonist | 0.107 0.069 DBMET00886 0.218 0.02 DBMET00921 | DBMET00921 | |
| 0.191 | 0.034 | 0.191 | Protein kinase (CK1) gamma 2 inhibitor | |||
| 0.173 | 0.017 | 0.173 | Death-associated protein kinase 1 inhibitor | 0.138 0.061 DBMET00830 | ||
| 0.197 | 0.041 | 0.197 | Protein kinase (CK1) inhibitor | |||
| 0.158 | 0.002 | 0.158 | MAP kinase kinase 7 inhibitor | 0.123 0.004 DBMET00830 0.095 0.018 DBMET00886 0.105 0.009 DBMET00921 | ||
| 0.195 | 0.043 | 0.347 | NOS3 expression enhancer | 0.328 0.014 DBMET00886 0.347 0.012 DBMET00921 | DBMET00921 | |
| 0.21 | 0.062 | 0.21 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | |||
| 0.183 | 0.041 | 0.183 | Cyclin-dependent kinase 7 inhibitor | 0.128 0.078 DBMET00921 | ||
| 0.148 | 0.009 | 0.148 | Histone deacetylase SIRT2 inhibitor | 0.108 0.023 DBMET00886 0.129 0.012 DBMET00921 | ||
| 0.171 | 0.033 | 0.171 | 5 Hydroxytryptamine 2B antagonist | |||
| 0.141 | 0.009 | 0.141 | Bombesin 1 receptor agonist | 0.116 0.014 DBMET00830 | ||
| 0.135 | 0.005 | 0.135 | Protein kinase C beta inhibitor | 0.09 0.019 DBMET00830 | ||
| 0.229 | 0.1 | 0.446 | 5 Hydroxytryptamine release stimulant | 0.446 0.037 DBMET00830 0.184 0.137 DBMET00921 | DBMET00830 | |
| 0.144 | 0.015 | 0.144 | Cyclin B3 inhibitor | 0.144 0.015 DBMET00830 | ||
| 0.185 | 0.056 | 0.185 | Phospholipase C inhibitor | 0.183 0.058 DBMET00830 0.139 0.131 DBMET00886 | ||
| 0.2 | 0.073 | 0.2 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | |||
| 0.196 | 0.07 | 0.196 | 5 Hydroxytryptamine 3E antagonist | 0.176 0.116 DBMET00921 | ||
| 0.154 | 0.027 | 0.173 | 5 Hydroxytryptamine 2A antagonist | 0.102 0.045 DBMET00886 0.173 0.023 DBMET00921 | DBMET00921 | |
| 0.141 | 0.015 | 0.141 | Cyclin A2 inhibitor | |||
| 0.131 | 0.005 | 0.131 | Poly(ADP-ribose) polymerase inhibitor | 0.056 0.019 DBMET00830 0.043 0.035 DBMET00886 0.051 0.022 DBMET00921 | ||
| 0.13 | 0.005 | 0.13 | 5 Hydroxytryptamine 1B agonist | 0.067 0.02 DBMET00830 | ||
| 0.149 | 0.024 | 0.149 | 5 Hydroxytryptamine 1 antagonist | 0.074 0.05 DBMET00921 | ||
| 0.194 | 0.07 | 0.194 | CDC-like kinase 2 inhibitor | |||
| 0.209 | 0.085 | 0.209 | HERG channel blocker | |||
| 0.153 | 0.031 | 0.153 | Protein kinase (CK2) inhibitor | |||
| 0.123 | 0.004 | 0.123 | Glutamate (mGluR1a) antagonist | 0.038 0.032 DBMET00921 | ||
| 0.141 | 0.029 | 0.153 | Opioid antagonist | 0.153 0.025 DBMET00886 0.15 0.026 DBMET00921 | DBMET00886 | |
| 0.145 | 0.035 | 0.145 | TRPA1 agonist | |||
| 0.125 | 0.016 | 0.125 | Cyclin A inhibitor | |||
| 0.133 | 0.024 | 0.133 | Polo-like kinase-1 inhibitor | 0.082 0.08 DBMET00921 | ||
| 0.127 | 0.018 | 0.127 | Check point kinase 1 inhibitor | |||
| 0.144 | 0.036 | 0.144 | Cyclin-dependent kinase 9 inhibitor | |||
| 0.132 | 0.025 | 0.132 | Pim-3 kinase inhibitor | 0.081 0.074 DBMET00921 | ||
| 0.148 | 0.041 | 0.177 | Cyclin-dependent kinase 5 inhibitor | 0.177 0.029 DBMET00830 | DBMET00830 | |
| 0.154 | 0.049 | 0.154 | MAP kinase kinase inhibitor | |||
| 0.218 | 0.114 | 0.218 | Transcription factor STAT inhibitor | |||
| 0.11 | 0.006 | 0.11 | Poly(ADP-ribose) polymerase 1 inhibitor | 0.05 0.017 DBMET00830 0.04 0.023 DBMET00921 | ||
| 0.131 | 0.027 | 0.131 | Alpha 2a adrenoreceptor antagonist | 0.083 0.046 DBMET00886 0.115 0.03 DBMET00921 | ||
| 0.114 | 0.01 | 0.114 | Protein kinase C epsilon inhibitor | 0.078 0.02 DBMET00830 | ||
| 0.125 | 0.025 | 0.125 | Opioid delta receptor antagonist | 0.102 0.029 DBMET00886 0.091 0.032 DBMET00921 | ||
| 0.112 | 0.014 | 0.112 | Protein kinase C eta inhibitor | 0.087 0.021 DBMET00830 | ||
| 0.118 | 0.021 | 0.267 | Dopamine agonist | 0.267 0.006 DBMET00886 0.222 0.008 DBMET00921 | DBMET00886 | |
| 0.118 | 0.021 | 0.118 | Phosphodiesterase 11A inhibitor | |||
| 0.118 | 0.021 | 0.118 | Phosphodiesterase XI inhibitor | |||
| 0.126 | 0.03 | 0.13 | Dopamine antagonist | 0.102 0.038 DBMET00886 0.13 0.029 DBMET00921 | DBMET00921 | |
| 0.113 | 0.018 | 0.113 | CDC7 inhibitor | |||
| 0.147 | 0.054 | 0.147 | Aurora-C kinase inhibitor | |||
| 0.119 | 0.027 | 0.126 | Dopamine D2 antagonist | 0.104 0.031 DBMET00886 0.126 0.026 DBMET00921 | DBMET00921 | |
| 0.097 | 0.007 | 0.097 | Dopamine D3 agonist | |||
| 0.099 | 0.011 | 0.117 | Dopamine D2 agonist | 0.117 0.009 DBMET00886 0.073 0.016 DBMET00921 | DBMET00886 | |
| 0.169 | 0.081 | 0.169 | LIM domain kinase 1 inhibitor | |||
| 0.113 | 0.027 | 0.127 | Opioid mu receptor antagonist | 0.127 0.023 DBMET00886 0.126 0.023 DBMET00921 | DBMET00886 | |
| 0.089 | 0.004 | 0.089 | 5 Hydroxytryptamine 1F agonist | 0.033 0.011 DBMET00830 | ||
| 0.118 | 0.033 | 0.118 | Glutamate (mGluR7) agonist | 0.095 0.072 DBMET00921 | ||
| 0.096 | 0.014 | 0.096 | Melanin-concentrating hormone receptor 1 antagonist | |||
| 0.173 | 0.093 | 0.173 | Amyloid beta aggregation inhibitor | |||
| 0.125 | 0.046 | 0.125 | Activin receptor-like kinase 4 inhibitor | |||
| 0.095 | 0.016 | 0.095 | Aryl hydrocarbon receptor antagonist | |||
| 0.14 | 0.061 | 0.166 | Cyclin-dependent kinase inhibitor | 0.166 0.049 DBMET00830 | DBMET00830 | |
| 0.083 | 0.005 | 0.083 | Poly(ADP-ribose) polymerase 2 inhibitor | |||
| 0.132 | 0.055 | 0.132 | Aurora-B kinase inhibitor | |||
| 0.101 | 0.024 | 0.11 | Dopamine D3 antagonist | 0.068 0.038 DBMET00886 0.11 0.022 DBMET00921 | DBMET00921 | |
| 0.125 | 0.052 | 0.28 | Cyclin-dependent kinase 1 inhibitor | 0.28 0.013 DBMET00830 | DBMET00830 | |
| 0.113 | 0.041 | 0.113 | Protein kinase C delta inhibitor | 0.088 0.065 DBMET00830 | ||
| 0.109 | 0.038 | 0.109 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | 0.088 0.059 DBMET00921 | ||
| 0.098 | 0.027 | 0.098 | Polo-like kinase-2 inhibitor | 0.072 0.051 DBMET00921 | ||
| 0.103 | 0.033 | 0.103 | Hematopoietic | |||
| 0.109 | 0.039 | 0.109 | Protein kinase A inhibitor | |||
| 0.123 | 0.054 | 0.123 | Transcription factor STAT6 inhibitor | |||
| 0.109 | 0.042 | 0.109 | Alpha 2 adrenoreceptor antagonist | 0.096 0.051 DBMET00921 | ||
| 0.235 | 0.168 | 0.235 | GABA C receptor rho-3 antagonist | 0.212 0.193 DBMET00830 | ||
| 0.076 | 0.011 | 0.088 | Kinesin-like protein 1 inhibitor | 0.041 0.021 DBMET00886 0.088 0.009 DBMET00921 | DBMET00921 | |
| 0.076 | 0.011 | 0.088 | Kinesin antagonist | 0.041 0.021 DBMET00886 0.088 0.009 DBMET00921 | DBMET00921 | |
| 0.126 | 0.062 | 0.126 | DNA repair enzyme inhibitor | |||
| 0.143 | 0.079 | 0.143 | MAP kinase 3 inhibitor | |||
| 0.082 | 0.019 | 0.082 | 5 Hydroxytryptamine 1A agonist | |||
| 0.19 | 0.128 | 0.239 | Spasmolytic | 0.239 0.096 DBMET00886 0.204 0.116 DBMET00921 | DBMET00886 | |
| 0.091 | 0.029 | 0.091 | 5 Hydroxytryptamine uptake inhibitor | |||
| 0.142 | 0.081 | 0.899 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.899 0.003 DBMET00830 | DBMET00830 | |
| 0.177 | 0.117 | 0.177 | Antiamyloidogenic | |||
| 0.088 | 0.029 | 0.088 | Protein kinase C alpha inhibitor | 0.087 0.029 DBMET00830 | ||
| 0.136 | 0.079 | 0.136 | Activin receptor-like kinase 2 inhibitor | |||
| 0.076 | 0.021 | 0.076 | Cyclin D1 inhibitor | |||
| 0.081 | 0.027 | 0.081 | 5 Hydroxytryptamine 2A agonist | 0.07 0.036 DBMET00830 0.058 0.049 DBMET00921 | ||
| 0.139 | 0.086 | 0.252 | Heat shock protein 90 antagonist | 0.252 0.02 DBMET00886 0.144 0.081 DBMET00921 | DBMET00886 | |
| 0.114 | 0.062 | 0.114 | MAP kinase 13 inhibitor | |||
| 0.13 | 0.078 | 0.13 | Glycogen synthase kinase-3 alpha inhibitor | 0.118 0.086 DBMET00830 | ||
| 0.074 | 0.023 | 0.074 | Histone deacetylase SIRT3 inhibitor | 0.059 0.051 DBMET00921 | ||
| 0.114 | 0.064 | 0.114 | CDK3/cyclin E inhibitor | |||
| 0.118 | 0.069 | 0.118 | TRKA antagonist | |||
| 0.072 | 0.023 | 0.072 | Pim-2 kinase inhibitor | |||
| 0.068 | 0.021 | 0.068 | 5 Hydroxytryptamine 7 agonist | |||
| 0.102 | 0.056 | 0.156 | Pim-1 kinase inhibitor | 0.156 0.025 DBMET00830 0.083 0.076 DBMET00921 | DBMET00830 | |
| 0.053 | 0.007 | 0.053 | Melatonin antagonist | |||
| 0.069 | 0.023 | 0.069 | Cyclin A1 inhibitor | 0.069 0.024 DBMET00921 | ||
| 0.066 | 0.021 | 0.066 | 5 Hydroxytryptamine 2 agonist | 0.057 0.03 DBMET00921 | ||
| 0.081 | 0.036 | 0.081 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.073 0.053 DBMET00830 | ||
| 0.106 | 0.061 | 0.292 | GABA C receptor agonist | 0.292 0.01 DBMET00830 | DBMET00830 | |
| 0.198 | 0.155 | 0.237 | 5 Hydroxytryptamine uptake stimulant | 0.235 0.097 DBMET00886 0.237 0.094 DBMET00921 | DBMET00921 | |
| 0.102 | 0.06 | 0.102 | Butyrylcholinesterase inhibitor | |||
| 0.107 | 0.065 | 0.107 | CDC-like kinase 3 inhibitor | |||
| 0.048 | 0.006 | 0.048 | LIM domain kinase 2 inhibitor | |||
| 0.05 | 0.008 | 0.05 | Protein 30S ribosomal subunit inhibitor | 0.022 0.02 DBMET00886 | ||
| 0.156 | 0.115 | 0.156 | Antimitotic | |||
| 0.101 | 0.06 | 0.101 | Insulin receptor antagonist | |||
| 0.135 | 0.096 | 0.135 | GABA C receptor rho-2 antagonist | 0.125 0.115 DBMET00830 | ||
| 0.082 | 0.043 | 0.082 | Rho-associated kinase II inhibitor | |||
| 0.116 | 0.077 | 0.116 | Protein kinase (CK1) delta inhibitor | |||
| 0.071 | 0.033 | 0.071 | Janus tyrosine kinase 1 inhibitor | |||
| 0.058 | 0.021 | 0.058 | Histamine H4 receptor antagonist | |||
| 0.08 | 0.043 | 0.08 | 5 Hydroxytryptamine 1F antagonist | 0.067 0.052 DBMET00921 | ||
| 0.078 | 0.042 | 0.078 | MAP3K7 inhibitor | |||
| 0.088 | 0.052 | 0.088 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | |||
| 0.064 | 0.032 | 0.064 | 5 Hydroxytryptamine 3 antagonist | |||
| 0.129 | 0.097 | 0.129 | Cholinergic | |||
| 0.096 | 0.065 | 0.096 | MAP kinase 8 inhibitor | |||
| 0.047 | 0.015 | 0.047 | Antibiotic Aminoglycoside-like | 0.036 0.025 DBMET00830 | ||
| 0.115 | 0.083 | 0.115 | Acetylcholinesterase inhibitor | |||
| 0.158 | 0.128 | 0.763 | Dyrk kinase inhibitor | 0.763 0.004 DBMET00830 | DBMET00830 | |
| 0.066 | 0.036 | 0.066 | Alpha 2 adrenoreceptor agonist | 0.054 0.051 DBMET00921 | ||
| 0.064 | 0.035 | 0.064 | Glutamate (mGluR1) antagonist | |||
| 0.073 | 0.044 | 0.073 | 5 Hydroxytryptamine 1A antagonist | |||
| 0.035 | 0.007 | 0.035 | Hedgehog signaling activator | |||
| 0.072 | 0.045 | 0.246 | CDK1/cyclin B1 inhibitor | 0.246 0.005 DBMET00830 | DBMET00830 | |
| 0.084 | 0.057 | 0.084 | 5 Hydroxytryptamine 2C antagonist | |||
| 0.068 | 0.041 | 0.07 | Dopamine D1 antagonist | 0.07 0.04 DBMET00886 | DBMET00886 | |
| 0.039 | 0.013 | 0.039 | Transforming growth factor beta 2 antagonist | |||
| 0.18 | 0.154 | 0.252 | DNA synthesis inhibitor | 0.212 0.106 DBMET00830 0.252 0.065 DBMET00886 0.199 0.124 DBMET00921 | DBMET00886 | |
| 0.098 | 0.072 | 0.098 | Cyclin-dependent kinase 2 inhibitor | |||
| 0.093 | 0.068 | 0.093 | MAP kinase 9 inhibitor | |||
| 0.038 | 0.013 | 0.038 | Complement C5a chemotactic receptor antagonist | 0.028 0.023 DBMET00830 | ||
| 0.137 | 0.113 | 0.137 | TRKC antagonist | |||
| 0.095 | 0.071 | 0.119 | Alpha 2c adrenoreceptor antagonist | 0.119 0.05 DBMET00921 | DBMET00921 | |
| 0.144 | 0.12 | 0.144 | Clk dual-specificity kinase inhibitor | |||
| 0.058 | 0.035 | 0.061 | Cyclin B2 inhibitor | 0.061 0.031 DBMET00830 | DBMET00830 | |
| 0.063 | 0.04 | 0.063 | CXC chemokine 4 receptor antagonist | |||
| 0.047 | 0.024 | 0.047 | Histamine H1 receptor agonist | 0.042 0.035 DBMET00830 | ||
| 0.199 | 0.177 | 0.199 | Vasodilator, peripheral | |||
| 0.131 | 0.11 | 0.284 | Heat shock protein 90 alpha antagonist | 0.284 0.017 DBMET00886 0.192 0.054 DBMET00921 | DBMET00886 | |
| 0.054 | 0.032 | 0.054 | Phosphodiesterase 7A inhibitor | 0.05 0.04 DBMET00921 | ||
| 0.042 | 0.021 | 0.042 | Protein kinase (CK1) epsilon inhibitor | |||
| 0.068 | 0.047 | 0.073 | Sirtuin 1 inhibitor | 0.066 0.05 DBMET00886 0.073 0.042 DBMET00921 | DBMET00921 | |
| 0.062 | 0.042 | 0.062 | Adrenaline uptake inhibitor | |||
| 0.036 | 0.016 | 0.036 | Protein kinase C beta I inhibitor | 0.033 0.026 DBMET00830 | ||
| 0.113 | 0.093 | 0.113 | Tyrosine-protein kinase receptor antagonist | |||
| 0.036 | 0.016 | 0.036 | Protein kinase C beta II inhibitor | |||
| 0.15 | 0.131 | 0.766 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.766 0.004 DBMET00830 | DBMET00830 | |
| 0.073 | 0.054 | 0.073 | Rho-associated kinase I inhibitor | |||
| 0.098 | 0.079 | 0.098 | Polo-like kinase-4 inhibitor | |||
| 0.043 | 0.025 | 0.05 | Factor XIa inhibitor | 0.05 0.018 DBMET00921 | DBMET00921 | |
| 0.054 | 0.037 | 0.054 | Lysine-specific demethylase 1A inhibitor | |||
| 0.035 | 0.018 | 0.035 | Protein kinase (CK2) beta inhibitor | |||
| 0.078 | 0.062 | 0.078 | ALK inhibitor | |||
| 0.06 | 0.044 | 0.062 | Cyclin B1 inhibitor | 0.062 0.041 DBMET00830 | DBMET00830 | |
| 0.08 | 0.064 | 0.08 | Transforming growth factor beta 3 antagonist | |||
| 0.02 | 0.004 | 0.02 | Antibiotic Tetracycline-like | 0.016 0.008 DBMET00886 0.015 0.011 DBMET00921 | ||
| 0.023 | 0.008 | 0.023 | Cyclin T1 inhibitor | |||
| 0.076 | 0.061 | 0.076 | TIE-2 antagonist | |||
| 0.024 | 0.009 | 0.024 | Melatonin 1 antagonist | |||
| 0.026 | 0.012 | 0.026 | Follicle-stimulating hormone agonist | |||
| 0.025 | 0.01 | 0.025 | Somatostatin 3 antagonist | 0.025 0.011 DBMET00830 | ||
| 0.084 | 0.069 | 0.084 | Potassium channel activator | |||
| 0.077 | 0.063 | 0.077 | TIE antagonist | |||
| 0.086 | 0.073 | 0.086 | CDK2/cyclin A inhibitor | |||
| 0.071 | 0.059 | 0.084 | Analgesic, opioid | 0.084 0.043 DBMET00886 0.077 0.051 DBMET00921 | DBMET00886 | |
| 0.051 | 0.039 | 0.059 | Dipeptidyl peptidase inhibitor | 0.059 0.027 DBMET00921 | DBMET00921 | |
| 0.056 | 0.044 | 0.056 | Protein kinase C iota inhibitor | |||
| 0.222 | 0.211 | 0.471 | Analgesic | 0.344 0.111 DBMET00886 0.471 0.058 DBMET00921 | DBMET00921 | |
| 0.054 | 0.043 | 0.054 | 5 Hydroxytryptamine 6 antagonist | |||
| 0.102 | 0.092 | 0.102 | Interleukin 8 antagonist | |||
| 0.047 | 0.038 | 0.047 | Chemokine receptor agonist | |||
| 0.046 | 0.036 | 0.046 | Dopamine transporter inhibitor | |||
| 0.128 | 0.119 | 0.128 | CDC-like kinase 4 inhibitor | |||
| 0.017 | 0.009 | 0.018 | CXC chemokine 4 receptor agonist | 0.018 0.007 DBMET00830 | DBMET00830 | |
| 0.051 | 0.045 | 0.053 | Cyclin B inhibitor | 0.053 0.041 DBMET00830 | DBMET00830 | |
| 0.054 | 0.048 | 0.054 | Cyclin H inhibitor | |||
| 0.047 | 0.042 | 0.047 | Potassium channel (Inward rectifier) activator | |||
| 0.034 | 0.028 | 0.034 | AMPA receptor agonist | |||
| 0.186 | 0.18 | 0.243 | Insulysin inhibitor | 0.193 0.169 DBMET00886 0.243 0.103 DBMET00921 | DBMET00921 | |
| 0.045 | 0.04 | 0.045 | Potassium channel (ATP-sensitive) activator | |||
| 0.032 | 0.028 | 0.033 | Somatostatin 5 agonist | 0.033 0.028 DBMET00830 | DBMET00830 | |
| 0.145 | 0.14 | 0.145 | Potassium channel blocker | |||
| 0.033 | 0.029 | 0.033 | 5 Hydroxytryptamine 3B antagonist | |||
| 0.041 | 0.038 | 0.042 | Dipeptidyl peptidase IV inhibitor | 0.042 0.037 DBMET00921 | DBMET00921 | |
| 0.079 | 0.077 | 0.079 | Potassium channel (Ca-activated) activator | |||
| 0.032 | 0.031 | 0.032 | Opioid delta receptor agonist | |||
| 0.116 | 0.116 | 0.189 | Thrombolytic | 0.189 0.057 DBMET00830 | DBMET00830 | |
| 0.061 | 0.061 | 0.091 | CDK2/cyclin E2 inhibitor | 0.091 0.031 DBMET00830 | DBMET00830 | |
| 0.009 | 0.01 | 0.011 | Melatonin 5 antagonist | 0.011 0.009 DBMET00921 | DBMET00921 | |
| 0.049 | 0.051 | 0.052 | Epithelial sodium channel blocker | 0.052 0.044 DBMET00830 | DBMET00830 | |
| 0.072 | 0.074 | 0.073 | Neuropeptide Y antagonist | 0.073 0.072 DBMET00921 | DBMET00921 | |
| 0.047 | 0.05 | 0.049 | Nicotinic alpha3beta2 receptor antagonist | 0.049 0.046 DBMET00921 | DBMET00921 | |
| 0.073 | 0.077 | 0.152 | CDK/cyclin complex inhibitor | 0.152 0.029 DBMET00830 | DBMET00830 | |
| 0.079 | 0.083 | 0.171 | Prolactin inhibitor | 0.149 0.023 DBMET00886 0.171 0.015 DBMET00921 | DBMET00921 | |
| 0.056 | 0.061 | 0.058 | Protease 3C (Human rhinovirus) inhibitor | 0.058 0.057 DBMET00921 | DBMET00921 | |
| 0.029 | 0.034 | 0.045 | Factor XI inhibitor | 0.045 0.012 DBMET00921 | DBMET00921 | |
| 0.105 | 0.115 | 0.146 | CDC-like kinase 1 inhibitor | 0.146 0.073 DBMET00830 | DBMET00830 | |
| 0.037 | 0.047 | 0.041 | Opioid mu receptor agonist | 0.041 0.039 DBMET00886 | DBMET00886 | |
| 0.068 | 0.083 | 0.134 | NMDA receptor antagonist | 0.134 0.03 DBMET00830 | DBMET00830 | |
| 0.032 | 0.05 | 0.041 | NMDA receptor subunit 3B antagonist | 0.041 0.034 DBMET00830 | DBMET00830 | |
| 0.062 | 0.08 | 0.089 | Somatostatin 1 agonist | 0.089 0.042 DBMET00830 0.075 0.057 DBMET00921 | DBMET00830 | |
| 0.027 | 0.048 | 0.047 | Dopamine D5 antagonist | 0.037 0.035 DBMET00886 0.047 0.027 DBMET00921 | DBMET00921 | |
| 0.042 | 0.065 | 0.073 | CC chemokine 2 receptor antagonist | 0.073 0.023 DBMET00921 | DBMET00921 | |
| 0.027 | 0.052 | 0.074 | 5 Hydroxytryptamine 2C agonist | 0.051 0.027 DBMET00886 0.074 0.013 DBMET00921 | DBMET00921 | |
| 0.062 | 0.089 | 0.115 | Adrenaline agonist | 0.115 0.028 DBMET00886 | DBMET00886 | |
| 0.037 | 0.064 | 0.061 | Cyclin E inhibitor | 0.061 0.04 DBMET00830 | DBMET00830 | |
| 0.043 | 0.07 | 0.179 | CDK1/cyclin B inhibitor | 0.179 0.011 DBMET00830 | DBMET00830 | |
| 0.065 | 0.093 | 0.133 | Antineoplastic alkaloid | 0.133 0.033 DBMET00886 0.083 0.062 DBMET00921 | DBMET00886 | |
| 0.019 | 0.049 | 0.029 | Somatostatin agonist | 0.029 0.024 DBMET00830 | DBMET00830 | |
| 0.01 | 0.044 | 0.017 | Factor IX inhibitor | 0.017 0.015 DBMET00830 | DBMET00830 | |
| 0.031 | 0.066 | 0.048 | Opioid agonist | 0.048 0.042 DBMET00886 | DBMET00886 | |
| 0.111 | 0.149 | 0.13 | Adenylate cyclase stimulant | 0.13 0.102 DBMET00830 | DBMET00830 | |
| 0.093 | 0.131 | 0.111 | Sphingosine 1-phosphate receptor 2 agonist | 0.111 0.073 DBMET00830 | DBMET00830 | |
| 0.045 | 0.084 | 0.055 | Heat shock protein 90 beta antagonist | 0.055 0.048 DBMET00886 | DBMET00886 | |
| 0.074 | 0.117 | 0.162 | Adenylate cyclase inhibitor | 0.15 0.045 DBMET00886 0.162 0.038 DBMET00921 | DBMET00921 | |
| 0.019 | 0.063 | 0.026 | Baculoviral IAP repeat-containing protein 4 inhibitor | 0.026 0.021 DBMET00921 | DBMET00921 | |
| 0.07 | 0.115 | 0.08 | CC chemokine 5 receptor agonist | 0.08 0.066 DBMET00921 | DBMET00921 | |
| 0.099 | 0.144 | 0.25 | Anticoagulant | 0.25 0.038 DBMET00830 | DBMET00830 | |
| 0.032 | 0.077 | 0.066 | CDK4/cyclin D1 inhibitor | 0.066 0.034 DBMET00830 | DBMET00830 | |
| 0.046 | 0.092 | 0.062 | Corticotropin releasing factor 2 receptor antagonist | 0.062 0.043 DBMET00921 | DBMET00921 | |
| 0.054 | 0.101 | 0.2 | Acetylcholine nicotinic agonist | 0.112 0.03 DBMET00886 0.2 0.008 DBMET00921 | DBMET00921 | |
| 0.133 | 0.182 | 0.346 | Interleukin agonist | 0.334 0.034 DBMET00886 0.346 0.03 DBMET00921 | DBMET00921 | |
| 0.029 | 0.08 | 0.074 | Plasminogen activator inhibitor | 0.074 0.029 DBMET00830 | DBMET00830 | |
| 0.019 | 0.071 | 0.04 | Factor VIIa inhibitor | 0.04 0.025 DBMET00921 | DBMET00921 | |
| 0.012 | 0.065 | 0.029 | Factor VII inhibitor | 0.029 0.021 DBMET00921 | DBMET00921 | |
| 0.027 | 0.082 | 0.045 | Plasmin inhibitor | 0.045 0.035 DBMET00830 | DBMET00830 | |
| 0.081 | 0.138 | 0.103 | Factor V inhibitor | 0.103 0.062 DBMET00830 | DBMET00830 | |
| 0.019 | 0.082 | 0.079 | Urokinase inhibitor | 0.079 0.021 DBMET00830 | DBMET00830 | |
| 0.027 | 0.089 | 0.039 | Glucose-6-phosphate dehydrogenase inhibitor | 0.038 0.025 DBMET00886 0.039 0.024 DBMET00921 | DBMET00921 | |
| 0.038 | 0.105 | 0.079 | Neuronal nicotinic receptor antagonist | 0.079 0.038 DBMET00921 | DBMET00921 | |
| 0.03 | 0.104 | 0.116 | Nicotinic alpha7 receptor agonist | 0.049 0.044 DBMET00886 0.116 0.007 DBMET00921 | DBMET00921 | |
| 0.027 | 0.103 | 0.133 | Nicotinic neuronal receptor agonist | 0.059 0.036 DBMET00886 0.133 0.007 DBMET00921 | DBMET00921 | |
| 0.049 | 0.129 | 0.11 | Prolactin release inhibitor | 0.099 0.005 DBMET00886 0.11 0.004 DBMET00921 | DBMET00921 | |
| 0.019 | 0.099 | 0.053 | Dopamine D5 agonist | 0.046 0.021 DBMET00830 0.053 0.016 DBMET00886 | DBMET00886 | |
| 0.046 | 0.127 | 0.071 | Trypsin inhibitor | 0.071 0.033 DBMET00830 | DBMET00830 | |
| 0.047 | 0.132 | 0.059 | Beta 2 adrenoreceptor agonist | 0.059 0.052 DBMET00886 | DBMET00886 | |
| 0.015 | 0.099 | 0.034 | Epoxide hydrolase 1 inhibitor | 0.034 0.016 DBMET00921 | DBMET00921 | |
| 0.044 | 0.129 | 0.08 | Acetylcholine nicotinic antagonist | 0.08 0.054 DBMET00921 | DBMET00921 | |
| 0.039 | 0.128 | 0.052 | Kallikrein 1 inhibitor | 0.052 0.048 DBMET00830 | DBMET00830 | |
| 0.02 | 0.111 | 0.067 | CDK2/cyclin E inhibitor | 0.067 0.037 DBMET00830 | DBMET00830 | |
| 0.009 | 0.102 | 0.046 | Dipeptidyl peptidase I inhibitor | 0.046 0.01 DBMET00921 | DBMET00921 | |
| 0.028 | 0.125 | 0.061 | Nicotinic receptor alpha7 subunit antagonist | 0.061 0.028 DBMET00921 | DBMET00921 | |
| 0.117 | 0.214 | 0.144 | Heat shock protein 70 antagonist | 0.144 0.06 DBMET00886 0.131 0.117 DBMET00921 | DBMET00886 | |
| 0.069 | 0.168 | 0.164 | Alpha-N-acetylglucosaminidase inhibitor | 0.145 0.058 DBMET00886 0.164 0.047 DBMET00921 | DBMET00921 | |
| 0.045 | 0.151 | 0.144 | Acetylcholine agonist | 0.144 0.028 DBMET00921 | DBMET00921 | |
| 0.063 | 0.172 | 0.103 | Nav1.4 sodium channel blocker | 0.093 0.087 DBMET00830 0.091 0.09 DBMET00886 0.103 0.072 DBMET00921 | DBMET00921 | |
| 0.009 | 0.12 | 0.054 | Dopamine D1 agonist | 0.054 0.004 DBMET00886 0.039 0.005 DBMET00921 | DBMET00886 | |
| 0.164 | 0.277 | 0.486 | Antibacterial | 0.486 0.045 DBMET00886 0.385 0.084 DBMET00921 | DBMET00886 | |
| 0.087 | 0.206 | 0.122 | Growth hormone agonist | 0.122 0.118 DBMET00921 | DBMET00921 | |
| 0.075 | 0.199 | 0.122 | Acetylcholine M1 receptor antagonist | 0.122 0.106 DBMET00886 | DBMET00886 | |
| 0.067 | 0.195 | 0.094 | Folate antagonist | 0.094 0.077 DBMET00830 | DBMET00830 | |
| 0.04 | 0.168 | 0.088 | Antiadrenergic | 0.088 0.064 DBMET00886 | DBMET00886 | |
| 0.038 | 0.169 | 0.086 | Adrenaline antagonist | 0.086 0.063 DBMET00886 | DBMET00886 | |
| 0.075 | 0.217 | 0.193 | Cell wall synthesis inhibitor | 0.172 0.045 DBMET00886 0.193 0.033 DBMET00921 | DBMET00921 | |
| 0.027 | 0.177 | 0.051 | Fatty acid synthase inhibitor | 0.051 0.05 DBMET00921 | DBMET00921 | |
| 0.093 | 0.244 | 0.16 | 3C-like protease (Human coronavirus) inhibitor | 0.16 0.085 DBMET00921 | DBMET00921 | |
| 0.052 | 0.21 | 0.148 | Acetylcholine antagonist | 0.148 0.051 DBMET00886 0.099 0.094 DBMET00921 | DBMET00886 | |
| 0.128 | 0.288 | 0.209 | Antithrombotic | 0.209 0.167 DBMET00830 | DBMET00830 | |
| 0.052 | 0.212 | 0.153 | Cholinergic antagonist | 0.153 0.051 DBMET00886 0.101 0.095 DBMET00921 | DBMET00886 | |
| 0.063 | 0.227 | 0.14 | Angiogenesis stimulant | 0.14 0.129 DBMET00830 | DBMET00830 | |
| 0.052 | 0.221 | 0.185 | Lipid peroxidase inhibitor | 0.185 0.048 DBMET00886 | DBMET00886 | |
| 0.011 | 0.183 | 0.13 | Nicotinic receptor beta4 subunit antagonist | 0.114 0.005 DBMET00886 0.13 0.005 DBMET00921 | DBMET00921 | |
| 0.129 | 0.307 | 0.404 | Antiobesity | 0.333 0.096 DBMET00886 0.404 0.064 DBMET00921 | DBMET00921 | |
| 0.013 | 0.207 | 0.059 | Acetylcholine M3 receptor antagonist | 0.059 0.042 DBMET00886 | DBMET00886 | |
| 0.105 | 0.306 | 0.218 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.218 0.059 DBMET00886 0.163 0.12 DBMET00921 | DBMET00886 | |
| 0.025 | 0.239 | 0.071 | Thrombin inhibitor | 0.071 0.054 DBMET00830 | DBMET00830 | |
| 0.024 | 0.239 | 0.108 | Androgen antagonist | 0.108 0.041 DBMET00886 0.099 0.047 DBMET00921 | DBMET00886 | |
| 0.08 | 0.298 | 0.12 | Papain-like protease (SARS coronavirus) inhibitor | 0.12 0.082 DBMET00886 0.117 0.09 DBMET00921 | DBMET00886 | |
| 0.015 | 0.235 | 0.062 | Neuraminidase (Influenza A) inhibitor | 0.055 0.017 DBMET00830 0.06 0.012 DBMET00886 0.062 0.011 DBMET00921 | DBMET00921 | |
| 0.019 | 0.242 | 0.088 | Nicotinic alpha4beta2 receptor antagonist | 0.088 0.042 DBMET00921 | DBMET00921 | |
| 0.011 | 0.241 | 0.065 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitor | 0.047 0.032 DBMET00886 0.065 0.02 DBMET00921 | DBMET00921 | |
| 0.04 | 0.271 | 0.094 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.094 0.06 DBMET00921 | DBMET00921 | |
| 0.02 | 0.257 | 0.054 | Sphingosine kinase inhibitor | 0.054 0.052 DBMET00830 | DBMET00830 | |
| 0.05 | 0.306 | 0.13 | Nav1.2 sodium channel blocker | 0.13 0.072 DBMET00921 | DBMET00921 | |
| 0.027 | 0.335 | 0.207 | Bronchodilator | 0.207 0.017 DBMET00886 0.099 0.065 DBMET00921 | DBMET00886 | |
| 0.021 | 0.331 | 0.063 | Bombesin 3 receptor antagonist | 0.063 0.03 DBMET00921 | DBMET00921 | |
| 0.016 | 0.327 | 0.055 | Sphingosine kinase 2 inhibitor | 0.055 0.038 DBMET00830 | DBMET00830 | |
| 0.014 | 0.325 | 0.057 | Androgen agonist | 0.057 0.046 DBMET00921 | DBMET00921 | |
| 0.048 | 0.362 | 0.143 | Amyloid beta precursor protein antagonist | 0.143 0.109 DBMET00886 | DBMET00886 | |
| 0.01 | 0.337 | 0.099 | Neuraminidase inhibitor | 0.099 0.016 DBMET00886 0.098 0.016 DBMET00921 | DBMET00886 | |
| 0.077 | 0.448 | 0.221 | Nootropic | 0.221 0.133 DBMET00921 | DBMET00921 | |
| 0.008 | 0.384 | 0.125 | Nicotinic receptor alpha4 subunit antagonist | 0.101 0.008 DBMET00886 0.125 0.005 DBMET00921 | DBMET00921 | |
| 0.01 | 0.418 | 0.044 | Mineralocorticoid receptor antagonist | 0.044 0.041 DBMET00921 | DBMET00921 | |
| 0.01 | 0.433 | 0.088 | Neuraminidase (influenza) inhibitor | 0.061 0.052 DBMET00830 0.088 0.02 DBMET00886 0.084 0.023 DBMET00921 | DBMET00886 | |
| 0.09 | 0.531 | 0.307 | Interleukin 2 agonist | 0.22 0.157 DBMET00830 0.307 0.069 DBMET00886 0.288 0.082 DBMET00921 | DBMET00886 | |
| 0.042 | 0.551 | 0.213 | Immunosuppressant | 0.213 0.184 DBMET00886 | DBMET00886 | |
| 0.006 | 0.603 | 0.061 | p53 inhibitor | 0.052 0.013 DBMET00886 0.061 0.008 DBMET00921 | DBMET00921 | |
| 0.007 | 0.737 | 0.121 | Cyclooxygenase 1 inhibitor | 0.121 0.079 DBMET00830 | DBMET00830 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |